Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis.

OBJECTIVE Smad3 (or, MADH3) is a key intracellular messenger in the transforming growth factor beta signaling pathway. In mice, Smad3 deficiency accelerates growth plate chondrocyte maturation and leads to an osteoarthritis (OA)-like disease. We undertook this study to investigate the role of genetic variation in SMAD3 in the risk of large-joint OA in humans. METHODS Ten tag single-nucleotide polymorphisms (SNPs) in the SMAD3 gene region were tested in a discovery set: 313 patients who had undergone total knee replacement, 214 patients who had undergone total hip replacement, and 520 controls from the UK. The SNP associated with both hip and knee OA was subsequently genotyped in 1,221 controls and 1,074 cases from 2 cohorts of patients with hip OA and 2,537 controls and 1,575 cases from 4 cohorts of patients with knee OA. RESULTS A SNP (rs12901499) mapping to intron 1 of SMAD3 was associated with both knee and hip OA (P < 0.0022 and P < 0.021, respectively) in the discovery set. In all study cohorts, the major allele (G) was increased among OA patients relative to controls. A meta-analysis for knee OA yielded an odds ratio (OR) of 1.22 (95% confidence interval [95% CI] 1.12-1.34), P < 7.5 x 10(-6). For hip OA, the OR was 1.22 (95% CI 1.09-1.36), P < 4.0 x 10(-4). No evidence for heterogeneity was found (I(2) = 0%). CONCLUSION Our data indicate that genetic variation in the SMAD3 gene is involved in the risk of both hip OA and knee OA in European populations, confirming the results from animal models on the potential importance of this molecule in the pathogenesis of OA.

[1]  Byron C. Wallace,et al.  Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data , 2009, BMC medical research methodology.

[2]  W. B. van den Berg,et al.  TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. , 2009, Osteoarthritis and cartilage.

[3]  A. Hofman,et al.  Variation at the ANP32A gene is associated with risk of hip osteoarthritis in women. , 2009, Arthritis and rheumatism.

[4]  C. Perreault,et al.  Differential expression of SMAD3 transcripts is not regulated by cis-acting genetic elements but has a gender specificity , 2009, Genes and Immunity.

[5]  T. Spector,et al.  Association of the DVWA and GDF5 polymorphisms with osteoarthritis in UK populations , 2008, Annals of the rheumatic diseases.

[6]  E. Schwarz,et al.  Induction of an osteoarthritis-like phenotype and degradation of phosphorylated Smad3 by Smurf2 in transgenic mice. , 2008, Arthritis and rheumatism.

[7]  A Hofman,et al.  Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.

[8]  L. Murphy,et al.  Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors , 2007, Molecular and Cellular Biochemistry.

[9]  H. Moses,et al.  A tale of two proteins: Differential roles and regulation of Smad2 and Smad3 in TGF‐β signaling , 2007, Journal of cellular biochemistry.

[10]  E. Schwarz,et al.  Smad3‐Deficient Chondrocytes Have Enhanced BMP Signaling and Accelerated Differentiation , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  Takayuki Furumatsu,et al.  Smad3 Induces Chondrogenesis through the Activation of SOX9 via CREB-binding Protein/p300 Recruitment*[boxs] , 2005, Journal of Biological Chemistry.

[12]  X. Yang,et al.  Mutation analysis of the Smad3 gene in human osteoarthritis , 2003, European Journal of Human Genetics.

[13]  C. Deng,et al.  TGF-β/Smad3 Signals Repress Chondrocyte Hypertrophic Differentiation and Are Required for Maintaining Articular Cartilage , 2001, The Journal of cell biology.

[14]  I Olkin,et al.  Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. , 2000, Statistics in medicine.